Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trialSusan E. Krown, Seán McCarthy, Wadzanai Samaneka et al.|The Lancet|2020Cited by 91
As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical TrialMina C. Hosseinipour, Minhee Kang, Susan E. Krown et al.|Clinical Infectious Diseases|2018Cited by 37
Early Progression and Immune Reconstitution Inflammatory Syndrome During Treatment of Mild-To-Moderate Kaposi Sarcoma in Sub-Saharan Africa and South America: Incidence, Long-Term Outcomes, and Effects of Early ChemotherapyMulinda Nyirenda, McNeil Ngongondo, Minhee Kang et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2020Cited by 15
Predictive Value of Serum Biomarkers for Response of Limited-Stage AIDS-Associated Kaposi Sarcoma to Antiretroviral Therapy With or Without Concomitant Chemotherapy in Resource-Limited SettingsMarta Epeldegui, Di Chang, Jeannette Y. Lee et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2023Cited by 15
Mortality and Associated Risk Factors Among People Living With HIV With Kaposi Sarcoma: A5263/AMC066 and A5264/AMC067Maganizo Chagomerana, Mina C. Hosseinipour, Carlee Moser et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2024Cited by 0